Dose reduction strategy can substantially reduce high cost of TNF inhibitor therapy in RA

(European League Against Rheumatism) The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that, in rheumatoid arthritis patients, a good clinical response to maintenance treatment with a tumor necrosis factor inhibitor was maintained even when the dose was reduced by one-third.